FDA Peptide Reclassification 2026: What Researchers Want FDA Peptide Reclassification 2026: What It Means for Providers The FDA just changed the game for peptides. April 2026 The FDA is reviewing Category 2 peptides for potential removal from restricted status. Full approval for some peptides may be BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Thinking about trying BPC 157? Read this first., While often marketed as a healing peptide BPC 157 is not FDA approved and not pharmacy grade meaning most versions sold online are unregulated, FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026 )